Theravance Inc. (THRX)
-NasdaqGS 37.52 
0.51(1.38%) 4:00PM EDT
| Prev Close: | 37.01 |
|---|
| Open: | 37.25 |
|---|
| Bid: | 37.36 x 100 |
|---|
| Ask: | 38.29 x 100 |
|---|
| 1y Target Est: | 43.00 |
|---|
| Beta: | 1.89 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 37.00 - 38.17 |
|---|
| 52wk Range: | 17.06 - 42.41 |
|---|
| Volume: | 1,263,012 |
|---|
| Avg Vol (3m): | 1,538,470 |
|---|
| Market Cap: | 3.73B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.51 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Elan Provides Strategic UpdateZacks(Tue 3:46PM EDT)
- Analysts: Microsoft Has Big Potential and 3 More Research Notes to Browseat Wall St. Cheat Sheet(Tue 3:13PM EDT)
- Elan Continues To Make Baffling Strategic Decisionat Investopedia(Tue 1:30PM EDT)
- Theravance pullback on Elan bid a buying opportunity, says Piper Jaffrayat theflyonthewall.com(Tue 7:07AM EDT)
- Royalty raises Elan bid, issues ultimatum to shareholdersat Reuters(Mon, May 20)
- Royalty Pharma increases bid for drugmaker ElanAP(Mon, May 20)
- The 3 Deadliest Diseases in the U.S.at Motley Fool(Mon, May 20)
- Royalty Pharma Raises Elan Bid to $12.50 a Shae in Cashat Bloomberg(Mon, May 20)
- THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 20)
- Elan Makes Two Acquisitions for $380 Millionat Bloomberg(Mon, May 20)
- This Week in Biotechat Motley Fool(Sat, May 18)
- The Billion Dollar COPD Deal: Who Gains The Most?at Seeking Alpha(Fri, May 17)
- A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical CompaniesWall Street Transcript(Thu, May 16)
- THERAVANCE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Thu, May 16)
- Theravance's CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 367.97 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.15 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.52 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | 0.09 |
|---|
Business Summary
Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)...
View More